Creation of Waterproof, TLD Probes for Dose Measurements to Validate Image-based Radiopharmaceutical Therapy Dosimetry Workflow

Overview

Journal Biomed Phys Eng Express

Specialties Biomedical Engineering
Biophysics

Date 2023 Apr 21

PMID 37084718

Authors

David P Adam

Clifford Hammer

Julia Ziege Malyshev

Wesley S Culberson

Tyler J Bradshaw

Joseph J Grudzinski

Paul M Harari

Bryan P Bednarz

Affiliations

Soon will be listed here.

Abstract

Voxel-level dosimetry based on nuclear medicine images offers patient-specific personalization of radiopharmaceutical therapy (RPT) treatments. Clinical evidence is emerging demonstrating improvements in treatment precision in patients when voxel-level dosimetry is used compared to MIRD. Voxel-level dosimetry requires absolute quantification of activity concentrations in the patient, but images from SPECT/CT scanners are not quantitative and require calibration using nuclear medicine phantoms. While phantom studies can validate a scanner's ability to recover activity concentrations, these studies provide only a surrogate for the true metric of interest: absorbed doses. Measurements using thermoluminescent dosimeters (TLDs) are a versatile and accurate method of measuring absorbed dose. In this work, a TLD probe was manufactured that can fit into currently available nuclear medicine phantoms for the measurement of absorbed dose of RPT agents. Next, 748 MBq of I-131 was administered to a 16 ml hollow source sphere placed in a 6.4 L Jaszczak phantom in addition to six TLD probes, each holding 4 TLD-100 1 × 1 × 1 mm TLD-100 (LiF:Mg,Ti) microcubes. The phantom then underwent a SPECT/CT scan in accordance with a standard SPECT/CT imaging protocol for I-131. The SPECT/CT images were then input into a Monte Carlo based RPT dosimetry platform named RAPID and a three dimensional dose distribution in the phantom was estimated. Additionally, a GEANT4 benchmarking scenario (denoted 'idealized') was created using a stylized representation of the phantom. There was good agreement for all six probes, the differences between measurement and RAPID ranged between -5.5% and 0.9%. The difference between the measured and the idealized GEANT4 scenario was calculated and ranged from -4.3% and -20.5%. This work demonstrates good agreement between TLD measurements and RAPID. In addition, it introduces a novel TLD probe that can be easily introduced into clinical nuclear medicine workflows to provide QA of image-based dosimetry for RPT treatments.

References

Giap H, Macey D, Bayouth J, Boyer A . Validation of a dose-point kernel convolution technique for internal dosimetry. Phys Med Biol. 1995; 40(3):365-81. DOI: 10.1088/0031-9155/40/3/003. View

Gregory R, Murray I, Gear J, Leek F, Chittenden S, Fenwick A . Standardised quantitative radioiodine SPECT/CT Imaging for multicentre dosimetry trials in molecular radiotherapy. Phys Med Biol. 2019; 64(24):245013. DOI: 10.1088/1361-6560/ab5b6c. View

Giap H, Macey D, Podoloff D . Development of a SPECT-based three-dimensional treatment planning system for radioimmunotherapy. J Nucl Med. 1995; 36(10):1885-94. View

Lawhn-Heath C, Hope T, Martinez J, Fung E, Shin J, Seo Y . Dosimetry in radionuclide therapy: the clinical role of measuring radiation dose. Lancet Oncol. 2022; 23(2):e75-e87. DOI: 10.1016/S1470-2045(21)00657-4. View

Pinter C, Lasso A, Wang A, Jaffray D, Fichtinger G . SlicerRT: radiation therapy research toolkit for 3D Slicer. Med Phys. 2012; 39(10):6332-8. DOI: 10.1118/1.4754659. View

Sgouros G, Dewaraja Y, Escorcia F, Graves S, Hope T, Iravani A . Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns. J Nucl Med. 2021; 62(Suppl 3):12S-22S. DOI: 10.2967/jnumed.121.262750. View

DArienzo M, Pimpinella M, Coste V, Capogni M, Ferrari P, Mariotti F . Absorbed dose measurements from a Y radionuclide liquid solution using LiF:Mg,Cu,P thermoluminescent dosimeters. Phys Med. 2020; 69:127-133. DOI: 10.1016/j.ejmp.2019.11.010. View

Nunn A, Davis S, Micka J, DeWerd L . LiF:Mg,Ti TLD response as a function of photon energy for moderately filtered x-ray spectra in the range of 20-250 kVp relative to 60Co. Med Phys. 2008; 35(5):1859-69. DOI: 10.1118/1.2898137. View

Schneider W, Bortfeld T, Schlegel W . Correlation between CT numbers and tissue parameters needed for Monte Carlo simulations of clinical dose distributions. Phys Med Biol. 2000; 45(2):459-78. DOI: 10.1088/0031-9155/45/2/314. View

10.

Adam D, Grudzinski J, Bormett I, Cox B, Marsh I, Bradshaw T . Validation of Monte Carlo I radiopharmaceutical dosimetry workflow using a 3D-printed anthropomorphic head and neck phantom. Med Phys. 2022; 49(8):5491-5503. PMC: 9388595. DOI: 10.1002/mp.15699. View

11.

Besemer A, Yang Y, Grudzinski J, Hall L, Bednarz B . Development and Validation of RAPID: A Patient-Specific Monte Carlo Three-Dimensional Internal Dosimetry Platform. Cancer Biother Radiopharm. 2018; 33(4):155-165. PMC: 5963670. DOI: 10.1089/cbr.2018.2451. View

12.

Ljungberg M, Sjogreen-Gleisner K . The accuracy of absorbed dose estimates in tumours determined by quantitative SPECT: a Monte Carlo study. Acta Oncol. 2011; 50(6):981-9. DOI: 10.3109/0284186X.2011.584559. View

13.

Klein J, Nguyen T, LAROQUE P, Kopher K, Williams J, Wessels B . Yttrium-90 and iodine-131 radioimmunoglobulin therapy of an experimental human hepatoma. Cancer Res. 1989; 49(22):6383-9. View

14.

Capala J, Graves S, Scott A, Sgouros G, James S, Zanzonico P . Dosimetry for Radiopharmaceutical Therapy: Current Practices and Commercial Resources. J Nucl Med. 2021; 62(Suppl 3):3S-11S. DOI: 10.2967/jnumed.121.262749. View

15.

Marcatili S, Pettinato C, Daniels S, Lewis G, Edwards P, Fanti S . Development and validation of RAYDOSE: a Geant4-based application for molecular radiotherapy. Phys Med Biol. 2013; 58(8):2491-508. DOI: 10.1088/0031-9155/58/8/2491. View